

Appl. No. 08/881,509

Amdt. Dated Sept. 3, 2003

Reply to Final Office Action of March 6, 2003 and Advisory Action of July 28, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of claims:

1. Canceled.
2. (Currently amended) An isolated nucleic acid which ~~codes for~~ encodes the α chain of a human T cell receptor, a single chain T cell receptor or a soluble T cell receptor fragment ~~and,~~ wherein said nucleic acid comprises a CDR3 region having a nucleotide sequence selected from the group consisting of:
 - (a) a nucleotide sequence ~~coding for the~~ which encodes an amino acid sequence (SEQ ID NO: 23)

~~YCL(X₁...X_n)SARQLTF~~

~~in which X₁...X_n represents a sequence of 3-4 amino acids, wherein the amino acid sequence X₁...X_n is selected from the group consisting of: the amino acid sequences~~

YCL VGG SARQLTF (SEQ: ID NO: 46),

YCL VLSG SARQLTF (SEQ: ID NO: 47),

YCL ATG SARQLTF (SEQ: ID NO: 48),

YCL VSG SARQLTF (SEQ: ID NO: 49),

Appl. No. 08/881,509

Amdt. Dated Sept. 3, 2003

Reply to Final Office Action of March 6, 2003 and Advisory Action of July 28, 2003

YCL DSG SARQLTF (SEQ. ID NO: 50),

YCL VVSG SARQLTF (SEQ. ID NO: 51),

YCL ALAG SARQLTF (SEQ. ID NO: 52),

YCL APSG SARQLTF (SEQ. ID NO: 53)

and YCL VGR SARQLTF (SEQ. ID NO: 54), and

(b) a nucleotide sequence which ~~codes for~~ encodes an amino acid sequence ~~with an~~ having equivalent recognition specificity, as achieved with a T cell receptor comprising a CDR3 region with the amino acid sequence of SEQ ID NO: 23, for the peptide component of the T cell receptor ligands wherein the CDR3 region is at least 90% identical with the amino sequence of (a); and wherein the T cell receptor comprising a CDR3 region with amino acid sequence of SEQ. ID NO: 23 specifically binds kidney carcinoma cells:

i) a CDR3 region amino acid sequence that has at least 90% identity with an amino acid sequence set forth in (a); and

ii) a recognition specificity for a peptide component of a ligand for the T cell receptor that is equivalent to the recognition specificity achieved with an amino acid sequence set forth in (a); and
wherein the T cell receptor specifically binds kidney carcinoma cells.

3. Canceled.

4. (Currently amended) A Nucleic acid as claimed in The nucleic acid of claim 2, wherein the amino acid sequence $X_1 \dots X_n$ is selected from the group consisting of amino acid

Appl. No. 08/881,509

Amdt. Dated Sept. 3, 2003

Reply to Final Office Action of March 6, 2003 and Advisory Action of July 28, 2003

sequences ~~VGG~~ (SEQ. ID NO: 46), ~~VLSG~~ (SEQ. ID NO: 47) and ~~ATG~~ (SEQ. ID NO: 48).

5. (Currently amended) A vector, wherein it said vector contains at least one copy of a the nucleic acid as ~~claimed in one of the claims 1 to 4~~ of claim 2.
6. (Currently amended) An isolated cell, wherein it said cell expresses a the nucleic acid as ~~claimed in claim 2 or 4~~ of claim 2.
7. (Currently amended) A cell, wherein it said cell is transformed with ~~a~~ the nucleic acid as ~~claimed in one of the claims 1 to 4 or with a vector as claimed in claim 5~~ of claim 2.
- 8-25. Canceled.
26. (Currently amended) A pharmaceutical composition which contains as an active component a nucleic acid as claimed in one of ~~the claims 2 or 4~~ claim 2, or a cell as claimed in claim 6 or 7 optionally together with other active components as well as common pharmaceutical auxiliary agents, additives or carrier substances.
- 27-46. Canceled.
47. Canceled.
48. (Not entered) A cell, wherein said cell is transformed with the vector of claim 5.
49. (Not entered) A pharmaceutical composition which contains as an active component a cell as claimed in claim 48 optionally together with other active components as well as common pharmaceutical auxiliary agents, additives or carrier substances.